Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Eisai has decided to withdraw the marketing authorization application (MAA) and discontinue development of the antiobesity agent KES524 (sibutramine hydrochloride monohydrate).
Subscribe to our email newsletter
Eisai obtained the exclusive rights to develop and market KES524 in Japan in an agreement with Abbott.
Eisai had submitted a MAA for the agent to the Japanese regulatory authorities in November 2007 based on results of clinical studies it conducted in Japan.
However, following Abbott’s recent suspension/withdrawal of the drug from some global markets including the US and Europe, the company has decided to withdraw the MAA and discontinue the development of antiobesity agent KES524.